Biofluid biomarkers across neurological disorders: a systematic meta‐analysis of shared and unique molecular signatures

Abstract

Background: A comprehensive analysis of proximity‐extension assay (PEA) proteomic studies have led to the development and validation of novel cerebrospinal fluid (CSF) biomarker panels for Alzheimer's disease (AD; Del Campo et al., 2022 Nat Aging ) and dementia with Lewy bodies (DLB; Del Campo et al., 2023 Nat Comm .).

The paper